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 expanded HPCs did not alter the electrophysiological prop-
erties in mice after I/R. Therefore, ex vivo   -catenin-medi-
ated HPC expansion may represent an attractive therapeutic 
option for cell transplantation treatment of myocardial in-
farction without electrophysiological side effects. 
 Copyright © 2009 S. Karger AG, Basel 
 Introduction 
 Myocardial ischemia (MI) is a leading cause of heart 
failure in western countries  [1] . Cell transplantation is a 
promising new therapy, and several studies have shown 
that transplanted cells can form viable grafts within the 
host myocardium  [2, 3] . Recent studies have revealed that 
various types of cells are useful in cell transplantation 
after MI, such as skeletal myoblasts  [4–6] , smooth muscle 
cells  [7] , bone marrow mononuclear cells  [8, 9] and hema-
topoietic progenitor cells (HPCs)  [10–12] . Each cell type 
may have its own profile of advantages, limitations and 
practicability issues. However, there are several lines of 
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 Abstract 
 Background: Hematopoietic progenitor cells (HPCs) can im-
prove cardiac function after myocardial infarction. However, 
occurrence of arrhythmias is a potential limitation of cell 
therapy. In this study, we investigated the cardiac electro-
physiological properties of ex vivo expanded HPCs, gener-
ated by   -catenin gene transfer, after transcoronary delivery 
in a murine model of ischemia/reperfusion (I/R) injury.  Meth-
ods and Results: To assess arrhythmia inducibility of ex vivo 
expanded HPCs, mice were subjected to I/R and assigned to 
sham operation (n = 8), I/R (n = 21) and HPC (n = 15) treat-
ment. Six weeks later, mice were subjected to long-term 
electrocardiogram recording and in vivo transvenous elec-
trophysiological study. After I/R, mice showed a significant 
prolongation of conduction and repolarization compared 
with sham-operated mice. There was a marked increase in 
ventricular ectopic activity in infarcted mice as compared 
with sham-operated mice. Cardiac electrophysiological pa-
rameters and ventricular ectopic activity were not altered in 
mice treated with HPCs in comparison with control I/R mice. 
 Conclusion: Transcoronary delivery of genetically ex vivo 
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evidence suggesting that cell replacement therapy may be 
accompanied by an increased arrhythmic risk.
 Early clinical and experimental studies of myoblast 
therapy have shown a concerning incidence of ventricu-
lar arrhythmias  [5, 13, 14] . Consistent with this clinical 
observation, basic studies have shown that myoblasts do 
not electrically couple with native myocardium in vivo 
 [15] and, when injected into the myocardium, tend to 
cluster near injection sites. In contrast, recent studies 
 using bone marrow-derived cell therapy have reported 
that a significant incidence of arrhythmias has not been 
observed  [8, 10] . Contrarily, in vitro studies on mesen-
chymal stem cells  [16] and embryonic stem cell-derived 
cardiomyocytes  [17] have shown them to be potentially 
arrhythmogenic. Albeit, a recent report on Langendorff-
perfused rat hearts showed no difference in arrhythmia 
vulnerability after mesenchymal stem cell treatment af-
ter MI in comparison with control MI  [18] .
 Furthermore, the relatively low number of progenitor 
cells and the difficulties of ex vivo expansion required for 
therapeutic application represents another major practi-
cal limitation  [19–21] . We recently reported that genetic 
modification of HPCs with   -catenin (  -catenin-HPCs) 
provided an unlimited ex vivo expansion of multipotent 
progenitor cells  [22] . Transplantation of   -catenin-HPCs 
limited infarct size, attenuated left ventricular (LV) re-
modeling and ameliorated LV function in a cell concen-
tration-dependent manner  [23] .
 In the present study, we specifically investigated the 
effects of genetically ex vivo expanded HPCs using
  -catenin gene transfer on cardiac electrophysiological 
properties.
 Methods 
  -Catenin Gene Transfer into HPCs 
 The cell line was generated and characterized as described 
previously  [22] . Briefly, human   -catenin cDNA was cloned in -
to the retroviral vector SF  -91-IRES-eGFP, and recombinant 
VSV-G-pseudotyped retroviruses were generated in the packag-
ing cell line Phoenix-gp. Lineage– (lin–) bone marrow cells were 
isolated from male C57BL/6 mice using a lineage depletion kit 
(Miltenyi Biotech, Bergisch Gladbach, Germany). Retroviral gene 
transfer into lin– bone marrow cells was performed in the pres-
ence of a stem cell cytokine cocktail consisting of 10 ng/ml recom-
binant murine interleukin-3 (rmIL-3), 50 ng/ml recombinant hu-
man IL-11 (rhIL-11), 50 ng/ml recombinant human fms-like ty-
rosine kinase 3 (rhFlt3) and 50 ng/ml recombinant murine stem 
cell factor (rmSCF; all from Cell Systems, St. Katharinen, Ger-
many) over 48 h and transduced with a multiplicity of infection 
of 10 with 8   g/ml polybrene (Sigma, Deisenhofen, Germany). 
Cells were cultured for 24 months in IMDM containing 10% FCS, 
2 m M  L -glutamine, 1% penicillin-streptomycin, 1 m M non-essen-
tial amino acids, 5  ! 10 –5  M 2-mercaptoethanol, 10 ng/ml rmIL-
3 and 50 ng/ml rmSCF (all from Cell Systems).
 Flow Cytometry Analysis 
 Staining with fluorescent conjugated c-kit-PE and Sca-1-FITC 
antibodies and corresponding isotype controls (BD Pharmingen, 
San Diego, Calif., USA) were performed in ice-cold phosphate-
buffered saline (pH 7.4) containing 2% FCS for 30 min at 4 ° C. 
Cells were analyzed using FACSCalibur and CellQuest software.
 I/R, Transcoronary Infusion and Infarct Analysis 
 All animal studies were in compliance with the Guide for the 
Care and Use of Laboratory Animals as published by the US Na-
tional Institutes of Health and were approved by the state of Low-
er Saxony.
 Male C57BL/6 mice (aged 10–12 weeks) were subjected to I/R 
and transcoronary infusion of cells as described previously  [24] . 
In brief, the left anterior descending artery was transiently li-
gated with an 8-0 Prolene slipknot for 120 min followed by re-
perfusion. Twenty-four hours after I/R, the left carotid artery 
was cannulized, a transarterial catheter was placed in the aortic 
root and cells or saline were infused (200   l volume). Forty-
eight hours after I/R, animals were sacrificed, the area at risk 
and early infarct size were assessed by Evan’s blue and 2,3,5-tri-
phenyltetrazolium chloride staining. In a separate group of ani-
mals, MI size was determined after 6 weeks in hematoxylin- and 
eosin-stained sections and quantified by polarized light micros-
copy (Zeiss Axiovert 100, Quantimet 500MC digital image ana-
lyzer).
 Ambulatory Electrocardiogram Telemetry 
 Before electrophysiological study, the mice underwent ambu-
latory electrocardiogram (ECG) recordings using implantable 
PhysioTel TA10EA-F20 radiotransmitters (Data Science Interna-
tional, St. Paul, Minn., USA), as we have described previously  [25–
27] . Radiotransmitters were implanted 6 weeks after sham opera-
tion (n = 8), I/R (n = 21) and cell therapy with   -catenin-HPCs 
after I/R (n = 15). All baseline surface ECG parameters were mea-
sured manually with online calipers by 2 investigators indepen-
dently. Both investigators were blinded to the therapy regimen of 
the mice studied. Rate-corrected QTc and JTc intervals were cal-
culated as described previously  [28] . Records consisting of  1 10% 
artifacts were excluded from further analysis. The mean heart 
rate was computed, and the occurrence of ventricular premature 
beats (VPBs), supraventricular and ventricular tachycardia and 
bradycardia were analyzed.
 Electrophysiology Study Protocol 
 Invasive electrophysiological studies were performed after 
ambulatory ECGs were collected 6 weeks after sham I/R, I/R and 
I/R with additional cell therapy, respectively. The methodology of 
mouse invasive electrophysiological study has been previously 
described in detail by us  [25, 26] . Surface ECG interval measure-
ments have been well defined in mice. QT and JT intervals were 
corrected for heart rate according to the formula proposed by 
Mitchell et al.  [28] . Measurements of surface ECG parameters 
were performed by consensus between 2 investigators. A 2-french 
octapolar catheter with an interelectrode interval of 0.5 mm 
(CIBer mouse EP; NuMed, Nicholville, N.Y., USA) was inserted 
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via a jugular vein cutdown approach into the apex of the right 
ventricle of the murine heart. Right ventricular stimulation was 
performed with the distal electrode and right atrial stimulation 
with the proximal electrode of the catheter, assuring a constant 
stimulation site. We used a standardized stimulation protocol for 
each electrophysiological study in all studied animals. Investiga-
tors were blinded to the therapy regime of the mouse studied. Pac-
ing and programmed stimulation were performed in anesthe-
tized mice, as previously reported  [25–27, 29] .
 Delivery of burst extrastimuli was performed in decreasing 
coupling intervals of 10 ms, until atrial conduction failed to re-
sult in ventricular depolarization. Atrial and ventricular refrac-
toriness and atrioventricular (AV) effective and functional re-
fractory periods were obtained using a standard programmed 
atrial stimulation protocol, as has been well described in hu-
mans and mice elsewhere  [26, 29] . After assessing standard elec-
trophysiological parameters, double and triple atrial and ven-
tricular testing of S2–S4 followed by burst atrial and ventricular 
pacing at a cycle length of 30 ms for a maximum of 1 min was 
applied to assess atrial and ventricular arrhythmia inducibility. 
The protocol was terminated after arrhythmia was reproducibly 
inducible. Inducibility of  1 3 repetitive supraventricular or ven-
tricular beats were defined as nonsustained,  1 30 s as sustained 
atrial or ventricular tachycardia. Diagnosis of atrial and ven-
tricular tachycardia in mice is well established and includes 
analysis of sudden rate change, identifiable P wave, QRS mor-
phology and duration in comparison with sinus rhythm and en-
docardial atrial and ventricular activation. Differentiation be-
tween atrial and ventricular tachycardia was done by consensus 
between 2 investigators. Mice were excluded from analysis if the 
catheter could not be adequately placed in the right ventricle or 
if mice did not recover from anesthesia after the study, indicat-
ing right ventricular perforation.
 Statistical Analysis 
 All continuous variables, such as cardiac dimensions, ECG in-
tervals and cardiac conduction properties were compared with 
sham, with data presented as the mean  8 standard deviation. 
Statistical analysis was performed with ANOVA followed by Bon-
ferroni post-hoc analysis. The occurrence of VPBs was compared 
with Fisher’s exact test for the comparison of categorical variables. 
Comparison of the incidence of inducible or spontaneous ar-
rhythmia was performed with Fisher’s exact test. A p value  ! 0.05 
was considered statistically significant.
 Results 
 In vitro Characterization of the HPC Line 
  -Catenin-transduced lin– cells survived and prolif-
erated in a cytokine cocktail of IL-3 and SCF for more 
than 24 months, whereas the viability of eGFP-trans-
duced control cells dramatically decreased after 22 days 
of culture  [22] .   -Catenin-transduced cells stably ex-
pressed ( 1 99%) hematopoietic stem cell markers Sca-1 
and c-kit ( fig. 1 ), but failed to express lineage markers of 
myeloid (CD11b, GR-1, CD11c), erythroid (TER119) and 
lymphoid (B220, CD3e, NK1.1, CD11c) lineages. The con-
stitutive   -catenin expression was gradually downregu-
lated in the HPC line during 40 weeks of culture through 
an unknown silencing mechanism, whereas   -catenin 
cDNA was stably integrated in   -catenin-HPCs at 1, 8, 
16, 24 and 40 weeks after transduction  [22] . In the present 
study, we used the HPC line after 18 months of generation 
and culture.
 Transcoronary   -Catenin-HPC Injection Reduces 
Infarct Size 
 The mortality rate during the whole study period did 
not differ between the groups of animals treated with 
HPCs (2/17), sham (1/9) and I/R (3/24).
 Six weeks after I/R, the hearts of all mice had antero-
lateral wall infarction. Injection of 1  ! 10 7   -catenin-
HPCs (n = 7) reduced the infarct size significantly com-
Li
n
ea
g
e
Sc
a-
1
FSC c-kit
99%
 Fig. 1. In vitro characterization of   -
catenin-transduced HPCs. Hematopoi-
etic progenitor surface marker profile of 
  -catenin-HPCs. Fluorescence intensity 
plots are shown in log scale. FSC = For-
ward scatter. 
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pared with saline-injected mice (n = 13; p  ! 0.01;  fig. 2 a). 
To determine the effect of   -catenin-HPCs on early in-
farct size, the hearts were isolated 48 h after I/R and 24 h 
after transcoronary cell delivery, respectively. The size of 
the area at risk during left coronary occlusion was com-
parable in the   -catenin-HPC-treated (n = 6) and saline-
injected (n = 6) hearts. However, infarct sizes were sig-
nificantly smaller in   -catenin-HPC-treated hearts (p  ! 
0.05 vs. saline;  fig. 2 b).
 Ambulatory ECG Telemetry 
 The total number of ambulatory ECGs performed and 
the results of the electrocardiographic data are summa-
rized in  table 1 . A significant prolongation of QRS, QT 
and QTc comparing sham mice with I/R mice was ob-
served. Cell therapy with   -catenin-HPCs after I/R did 
not significantly alter any ECG parameter as compared 
with I/R ( table 1 ).
 During a of 12-hour Holter recording, there was no 
significant difference in heart rate between the studied 
groups. Significantly more ( 6 100 VPBs/12 h; p  ! 0.05) 
spontaneous VPBs occurred in mice after I/R as com-
pared with sham controls ( fig. 3 ). After cell transplanta-
tion in I/R, there was no significant difference in the oc-
currence of VPBs as compared with I/R.
 Electrophysiological Study Protocol 
 The total number of animals with completed electro-
physiological study and the results of surface ECG pa-
rameters of the electrophysiological data are summarized 
in  table 2 .
 Cardiac Conduction Properties and 
Electrophysiological Data 
 There was no significant difference in the groups with 
regard to sinus node function and AV conduction (AV 
interval, AV Wenckebach cycle length, AV 2:  1, AV effec-
tive refractory periods, AV functional refractory peri-
ods). The ventricular refractory period was increased sig-
nificantly in I/R and   -catenin-HPC mice compared 
with sham controls.
0
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 Fig. 2. Transcoronary HPC injection re-
duces infarct size.  a Quantification of in-
farct size by morphometric analysis in sa-
line- (n = 13) and   -catenin-HPC-treated 
(n = 7) mice. The infarct size was greater 
after saline injection and was reduced af-
ter injection of   -catenin-HPCs.  * * p  ! 
0.01 versus saline.  b The area at risk (AAR) 
and infarcted area (MI) were expressed as 
percentage of the LV cross-sectional area 
(LV); MI was also calculated as percentage 
of AAR.  * p  ! 0.05 versus saline. 
Table 1. Surface ECG conduction intervals in mice during ambulatory ECG recording
n RR
ms
P
ms
PR
ms
QRS
ms
QT
ms
QTc
ms
JT
ms
JTc
ms
Sham 8 9684 1382 3882 981 5386 5085 4486 4185
I/R 21 10085 1184 3583 1584** 6388** 5985** 4887 4685
-Catenin-HPCs 15 9885 1283 3683 1683** 6387** 5984** 4788 4485
RR = RR interval; P = duration of P wave; PR = duration of PR interval; QRS = duration of QRS interval;
QT = duration of QT interval; QTc = rate-corrected duration of QT interval; JT = duration of JT interval;
JTc = rate-corrected duration of JT interval. ** p < 0.01, compared with sham.
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 Programmed Stimulation and Arrhythmia 
Inducibility 
 With standard programmed electrical stimulation 
protocols and burst atrial and ventricular pacing, prov-
ocation of ectopic or reentrant rhythms was attempted. 
No animal experienced spontaneous ventricular ar-
rhythmias during placement of the catheter. Nonsus-
tained ventricular tachycardia was inducible in 1 sham 
and 1 I/R mouse. Therapy with   -catenin-HPCs did not 
enhance ventricular vulnerability – no ventricular 
–2.0
–1.5
–1.0
–0.5
0
0.5
V
b
7:19:01.8 7:19:02.0 7:19:02.2 7:19:02.4 7:19:02.6
Time
VPB VPB VPB VPB
7:19:02.8
V
a
0.8
–0.8
–0.4
0
0.4
10:34:09.4 10:34:09.6 10:34:09.8 10:34:10.0 10:34:10.2
VPB
VPB VPB VPB
 Fig. 3. Long-term ECG recording in mice. 
Representative recording of VPBs during 
long-term ECG recording in an I/R ( a ) and 
  -catenin-HPC ( b ) mouse. 
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tachycardia was inducible in these mice (0/7 mice). Atri-
al tachycardia/atrial fibrillation was inducible in 1 sham, 
2 I/R and 1   -catenin-HPC mouse; there was no statis-
tically significant difference in any of the compared 
groups.
 Discussion 
 In the present study, we show that I/R in mice alters 
cardiac electrophysiology by prolonging repolarization 
and ventricular refractoriness as well as by facilitating 
ventricular automaticity, as has been shown by us and 
various other groups previously  [26, 27, 30, 31] . The major 
finding of this study is that transaortal high-dose cell 
transplantation with genetically modified HPCs does not 
alter cardiac electrophysiology in vivo or enhance ven-
tricular automaticity in mice after I/R. We previously de-
scribed genetic modification of HPCs with   -catenin,
i.e.,   -catenin-HPCs, as a strategy for ex vivo expansion 
of HPCs providing unlimited access for repair of dam-
aged myocardium  [22] . Furthermore, we reported that 
  -catenin-HPC transplantation caused a reduction in MI 
size, enhanced angiogenesis and antiapoptotic effects, as-
sociated with improvement in cardiac function in a cell 
dose-dependent manner  [23] . Thus, cell therapy with ge-
netically modified HPCs after myocardial infarction in 
mice seems to be safe with regard to ventricular sponta-
neity and susceptibility to arrhythmias.
 Fatal cardiac arrhythmias are a major limiting factor 
for cell transplantation therapy in myocardial infarc-
tion. It is well recognized that transplantation of skeletal 
myoblasts after myocardial diseases can promote ma-
lignant arrhythmias both in animal models and in hu-
man studies  [5, 32, 33] . It has been postulated that the 
absence of apparent gap-junctional coupling of skeletal 
myoblasts to native cardiomyocytes may enhance non-
uniformity of conduction, hence precipitating arrhyth-
mias  [15, 34] .
 By contrast, transplanted stem cells show clear histo-
logical evidence of gap-junctional formation and contact 
with host tissue in animal studies, but in vitro studies on 
mesenchymal stem cells and embryonic stem cell-de-
rived cardiomyocytes have shown them to be potentially 
arrhythmogenic because they differentiated heteroge-
neously, were spontaneously active, had abnormal action 
potentials and showed a high proclivity towards arrhyth-
mia induction  [16, 17] . On the other hand, less arrhyth-
mic risk has been seen in human trials involving bone 
marrow-derived cells, which supports our results  [8, 10, 
35] . Nevertheless, further histological and electrophysi-
ological mapping experiments have to be performed in 
future to address these issues.
 In the present study, a transcoronary approach after 
transient MI was chosen to mimic the everyday clinical 
situation of rescue angioplasty and cell therapy. After the 
occluded coronary artery was reperfused, cells were in-
fused via a transcoronary approach to ensure that a high 
concentration of cells reached the infarcted myocardium. 
Injection of cells directly into the scared myocardium, as 
has been performed in several animal and human studies 
previously  [13, 14, 17] , may promote the forming of iso-
lated islets, which may per se enhance ventricular auto-
maticity and facilitate arrhythmias.
 Furthermore, we provide evidence that the transplan-
tation of large numbers of cells is safe in terms of arrhyth-
mogenicity. Limited cell quantity is a major problem for 
cell therapy with progenitor cells. Previous studies trans-
planted a few hundred thousand cells per animal after 
experimental myocardial infarction  [30, 32, 36] . Since we 
previously demonstrated that myocardial recovery after 
infarction was dependent on the amount of cells trans-
planted  [23] , we generated a novel multipotent hemato-
poietic cell line with a stable expression of Sca-1+ and
Table 2. Electrophysiological data summary
n SNRT
ms
WB
ms
AV 2:1
ms
AVERP
ms
VERP (S2)
ms
VERP (S3)
ms
VERP (S4)
ms
Sham 7 17789 9484 6488 5188 2583 2682 3184
I/R 13 178835 10189 6588 56810 3388* 3388* 4089*
-Catenin-HPCs 7 185815 9884 6285 5584 3587* 3689* 4389*
SNRT = Sinus node recovery time; WB = Wenckebach block; AV 2:1 = atrioventricular 2:1 conduction; 
AVERP = atrioventricular effective refractory period; VERP = ventricular effective refractory period. * p < 0.05, 
compared with sham.
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c-kit+ by overexpressing   -catenin in HPCs using a ret-
roviral vector to have access to an unlimited amount of 
cells  [22] . Consecutively, as many as ten million cells were 
transplanted using a transcoronary approach after I/R 
per mouse.
 The possibility that gene-manipulated cells which en-
hance angiogenesis and have antiapoptotic effects associ-
ated with improvement in cardiac function may promote 
local heterogeneity of ischemic myocardium, resulting in 
unstable reentry, slowed conduction or altered repolar-
ization, constitutes a potential complication of this ther-
apy. Few studies have previously been performed to eval-
uate safety of gene therapy in myocardial infarction. In a 
study with 25 patients undergoing vascular endothelial 
growth factor gene transfer for therapeutic angiogenesis, 
no complications were reported  [37] . Shintani et al.  [38] 
recently reported a reduction in infarct size after a com-
bined therapy with CD34+ cells and vascular endothelial 
growth factor 2 gene therapy in a rat model of MI. No 
major safety concerns and adverse events were reported. 
Our data indicate that genetic manipulation of HPCs per 
se does not enhance ventricular automaticity. There was 
no difference in the electrophysiological properties of 
mice treated with   -catenin-HPCs after I/R compared 
with untreated animals. This finding may be explained 
by the fact that in both groups, there was a cardiac dam-
age and scar. Thus, a substrate for ventricular automatic-
ity was induced by ischemia in both groups of animals, 
although the LV function was better after cell transplan-
tation. Cell transplantation does not seem to have modi-
fied the substrate for arrhythmias since repolarization 
and ventricular refractoriness were also altered in the 
same manner.
 Limitations 
 In vivo electrophysiological testing in mice may not be 
relevantly extrapolated to human clinical diseases, but 
provide an opportunity for hypothesis testing and under-
standing the pathology of clinically relevant cardiac elec-
trophysiology. A specific limitation of this study is that 
we do not present data of a control group, i.e., we did not 
perform cell therapy experiments with cells without   -
catenin transduction. The reason is that such large num-
bers of c-kit+/Sca-1+ cells can only be obtained by   -
catenin gene transfer and the generation of a cell line. 
Therapy with a significantly lower number of cells would 
not fulfill the criteria for an appropriate control group. 
However, as previously reported, the constitutive   -
catenin expression was gradually downregulated in the 
HPC line during 40 weeks of culture through an un-
known silencing mechanism, whereas   -catenin cDNA 
was stably integrated. These results suggest that ectopic 
expression of   -catenin immortalizes HPCs, but its ex-
pression is not required for their survival, proliferation 
and maintenance. In the present study, we used the HPC 
line after 18 months of generation and culture. Therefore, 
a direct influence of   -catenin on cell retention and cel-
lular action cannot be addressed.
 Since an I/R mouse model in contrast to permanent 
myocardial infarction was implemented, infarct size was 
relatively small. This may have resulted in fewer sponta-
neous as well as inducible arrhythmias.
 Furthermore, no data are presented on the arrhyth-
mogenicity of the ischemic border zone. Additional opti-
cal mapping techniques, which would provide mechanis-
tic information on conduction velocity and dispersion, 
should be performed in future studies to further address 
this issue.
 A further limitation may be the fact that, as previ-
ously reported, transcoronary injected cells did not 
show long-term, sustained engraftment ( 1 24 h) in the 
scared myocardium. On the other hand, we showed 
neovascularization in the ischemic myocardium, re-
duced apoptosis and formation of tube-like structures 
in vitro in a cell number-dependent manner  [23] . Nev-
ertheless, it can be stated that these beneficial effects are 
not accompanied by adverse alteration of cardiac elec-
trophysiology or enhanced ventricular spontaneity in 
mice in vivo.
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